MARIMED INC.
MariMed is a U.S. cannabis operator headquartered in Norwood, Massachusetts. It develops, owns, and manages state-licensed facilities for cultivating, processing, and dispensing medical and adult-use cannabis. Its proprietary brands include Nature’s Heritage flower, vapes, and concentrates; Betty’s Eddies fruit chews; Bubby’s Baked goods and hot chocolate mix; Vibations drink mix; and InHouse flower, vapes, and edibles. MariMed also licenses its brands in select domestic markets. MariMed earns money by selling its products wholesale to dispensaries operated by other license holders and through its own Thrive-branded dispensaries, which sell both MariMed products and products from other cannabis businesses. It also receives limited income from licensing, management fees, and real estate. The company operates in Massachusetts, Delaware, Illinois, Maryland, and Ohio, and manages a client’s cultivation and manufacturing operations in Pennsylvania.
No SEC Form 4 filings for $MRMD in the last 30 days.
See all $MRMD insider activity →MARIMED INC. (MRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MariMed Reports Third Quarter 2026 Earnings NORWOOD, MA, November 11, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for t
MariMed reported Q3 Non-GAAP EPS of -$0.01 and revenue of $44.2M, exceeding estimates by $3M. Revenue grew 8.4% year-over-year. The company's cash position increased to $10.4M, the highest in two years. Shares rose 2.76%.
MARIMED INC. (MRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 MariMed Stockholders Approve Proposed Reverse Stock Split NORWOOD, MA, October 29, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that the Compa
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MRMD (MARIMED INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent MRMD coverage spans corporate actions, earnings and insider activity.
Earnings beat revenue expectations and show cash‑flow positivity, likely supporting short‑term price appreciation.
MariMed reported Q3 Non-GAAP EPS of -$0.01 and revenue of $44.2M, exceeding estimates by $3M. Revenue grew 8.4% year-over-year. The company's cash position increased to $10.4M, the highest in two years. Shares rose 2.76%.
The approval could lead to short-term price volatility as investors assess the split's impact on liquidity and potential uplisting.
The approval may lead to a reverse split, potentially reducing share count and increasing price per share.
Potential reduction in share count and higher per‑share price may attract institutional investors if a U.S. exchange listing is achieved.
AlphAI scores every news story that mentions MRMD with an AI model for sentiment and relevance, and aggregates insider trades from MARIMED INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MARIMED INC. (MRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MariMed Reports Third Quarter 2026 Earnings NORWOOD, MA, November 11, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for t
MariMed reported Q3 Non-GAAP EPS of -$0.01 and revenue of $44.2M, exceeding estimates by $3M. Revenue grew 8.4% year-over-year. The company's cash position increased to $10.4M, the highest in two years. Shares rose 2.76%.
MARIMED INC. (MRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 MariMed Stockholders Approve Proposed Reverse Stock Split NORWOOD, MA, October 29, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that the Compa
MariMed (MRMD) shareholders approved a reverse stock split, with the board authorized to set a ratio between 1:50 and 1:100. The final ratio will depend on market conditions, according to the company.
MARIMED INC. (MRMD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MariMed Files Definitive Proxy Statement for Special Meeting of Stockholders to Approve Proposed Reverse Stock Split NORWOOD, MA, September 23, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused
MariMed Inc. (CSE: MRMD, OTCQB: MRMD) filed a proxy statement for a special meeting to seek shareholder approval for a proposed reverse stock split. The split, if approved, would allow the company to meet requirements for a potential U.S. exchange listing. The board will decide the final ratio and implementation. The meeting is scheduled for October 28, 2026.
MariMed reported record revenue in its latest quarter, driven by retail and wholesale growth. CEO Jon Levine attributed the success to investments in operations, brand development, and market expansion. The company's brands, like Betty's Eddies, lead in their respective states. Levine expects federal cannabis rescheduling could boost the sector and close the valuation gap for MariMed.
MARIMED INC. (MRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MariMed Reports Second Quarter 2026 Earnings NORWOOD, MA, August 12, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for th
MARIMED INC. (MRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. mrmd-20260604 0001522767 FALSE 0001522767 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
Levine Jon R (President and CEO) purchased 3,000 shares of MARIMED INC. (MRMD) at $0.08 on 2026-05-22.
